Literature DB >> 23039318

Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach.

Marco P Donadini1, Walter Ageno, James D Douketis.   

Abstract

Anticoagulant drugs are highly effective for the prevention and treatment of venous and arterial thromboembolism. However, their use is also associated with an increased risk for bleeding, with an associated ∼10% case-fatality rate. Appropriate strategies for the management and reversal of anticoagulant-associated bleeding are clinically important and, ideally, should be standardized. These include general resuscitation, and diagnosis and local treatment of the bleeding source, and one or more of the following interventions: transfusion of red cells; transfusion of clotting factor replacements; and administration of anticoagulant antidotes and other prohaemostatic agents. Reversal strategies for the 'conventional' anticoagulants are based largely on clinical evidence, whereas evidence to guide the management of bleeding associated with 'new' anticoagulants is emerging. This review provides an evidence-based, but practical, patient-focused approach for the management of bleeding associated with the old and new anticoagulants.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23039318     DOI: 10.2165/11641160-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  55 in total

1.  Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.

Authors:  James D Douketis; Karin Arneklev; Samuel Z Goldhaber; John Spandorfer; Frank Halperin; Jay Horrow
Journal:  Arch Intern Med       Date:  2006-04-24

2.  Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.

Authors:  Elsa P Bianchini; Judicael Fazavana; Veronique Picard; Delphine Borgel
Journal:  Blood       Date:  2010-11-03       Impact factor: 22.113

Review 3.  Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents.

Authors:  M Levi; E Eerenberg; P W Kamphuisen
Journal:  J Thromb Haemost       Date:  2011-09       Impact factor: 5.824

4.  Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.

Authors:  Harry R Büller; Alex S Gallus; Gerard Pillion; Martin H Prins; Gary E Raskob
Journal:  Lancet       Date:  2011-11-28       Impact factor: 79.321

5.  Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.

Authors:  Francesco Dentali; Chiara Marchesi; Matteo Giorgi Pierfranceschi; Mark Crowther; David Garcia; Elaine Hylek; Daniel M Witt; Nathan P Clark; Alessandro Squizzato; Davide Imberti; Walter Ageno
Journal:  Thromb Haemost       Date:  2011-07-28       Impact factor: 5.249

6.  Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin.

Authors:  H J Ng; L P Koh; L H Lee
Journal:  Ann Hematol       Date:  2003-03-08       Impact factor: 3.673

7.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

8.  Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

Authors:  Wei Zhou; Sönke Schwarting; Sergio Illanes; Arthur Liesz; Moritz Middelhoff; Markus Zorn; Martin Bendszus; Sabine Heiland; Joanne van Ryn; Roland Veltkamp
Journal:  Stroke       Date:  2011-10-13       Impact factor: 7.914

9.  Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.

Authors:  I Paty; M Trellu; J-M Destors; P Cortez; E Boëlle; G Sanderink
Journal:  J Thromb Haemost       Date:  2010-01-17       Impact factor: 5.824

10.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

Authors:  H R Büller; B L Davidson; H Decousus; A Gallus; M Gent; F Piovella; M H Prins; G Raskob; A E M van den Berg-Segers; R Cariou; O Leeuwenkamp; A W A Lensing
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

View more
  2 in total

Review 1.  Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Authors:  Celeste B Burness; Caroline M Perry
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

Review 2.  Rivaroxaban and hemostasis in emergency care.

Authors:  Jürgen Koscielny; Edita Rutkauskaite
Journal:  Emerg Med Int       Date:  2014-02-20       Impact factor: 1.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.